Contribution of interleukin-6/gp 130 signaling in hepatocytes to the inflammatory response in mice infected with Streptococcus pyogenes.

BACKGROUND Sepsis and septic shock caused by gram-positive bacteria have become increasingly frequent clinical problems. These conditions are accompanied by an overwhelming inflammation in which the liver plays a central role as a source and target of inflammatory mediators. Sepsis is still associated with high mortality rates, and new intervention strategies directed at ameliorating the extent of the inflammatory reaction are strongly needed. Here, we investigated whether blockage of the transducer gp130, a receptor involved in the regulation of the inflammatory response, might be useful in the treatment of experimental gram-positive sepsis. METHODS An experimental model of gram-positive sepsis was used in which liver-specific gp130-deficient mice (FVB/n alfpCre+ gp130(LoxP/LoxP)) and wild-type mice (FVB/n gp130(LoxP/LoxP)) were intravenously infected with Streptococcus pyogenes. The following parameters were monitored: mortality, bacterial loads in systemic organs, serum inflammatory cytokine levels, and organ damage. RESULTS We show that infected gp130-deficient mice survived significantly longer, had lower bacterial loads, and developed organ damage more slowly than infected wild-type mice. Furthermore, levels of interferon- gamma , interleukin-6, and the chemokine cytokine-induced neutrophil chemoattractant were significantly lower in gp130-deficient mice than in wild-type mice. Histopathological examination of livers showed lower amounts of neutrophil infiltration, apoptosis, and tissue damage in infected gp130-deficient mice than in wild-type mice. CONCLUSION Our results demonstrate that the gp130 receptor is involved in the regulation of inflammation during gram-positive sepsis and that blockage of gp130 signaling in hepatocytes could constitute a novel target for adjunctive therapy in patients with sepsis.

[1]  L. Lanier,et al.  Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.

[2]  H. Schild,et al.  Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27 , 2006, The Journal of experimental medicine.

[3]  B. Holzmann,et al.  Organ-Specific Role of MyD88 for Gene Regulation during Polymicrobial Peritonitis , 2006, Infection and Immunity.

[4]  C. Fielding,et al.  Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.

[5]  R. Baron,et al.  Pathobiology of sepsis: are we still asking the same questions? , 2006, American journal of respiratory cell and molecular biology.

[6]  C. Hunter New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions , 2005, Nature Reviews Immunology.

[7]  M. Neurath,et al.  Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.

[8]  M. Kohanawa,et al.  Endogenous Interleukin-6 Plays a Crucial Protective Role in Streptococcal Toxic Shock Syndrome via Suppression of Tumor Necrosis Factor Alpha Production , 2005, Infection and Immunity.

[9]  M. Manns,et al.  The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. , 2005, The Journal of clinical investigation.

[10]  M. Béné,et al.  A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis , 2004, The Journal of experimental medicine.

[11]  P. Heinrich,et al.  Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor* , 2004, Journal of Biological Chemistry.

[12]  C. Coopersmith,et al.  Antibiotics Improve Survival in Sepsis Independent of Injury Severity but do not Change Mortality in Mice with Markedly Elevated Interleukin 6 Levels , 2004, Shock.

[13]  F. Bozza,et al.  Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. , 2004, Shock.

[14]  Duncan Young,et al.  Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland , 2003, Critical care medicine.

[15]  M. Manns,et al.  Lack of gp130 expression in hepatocytes promotes liver injury. , 2003, Gastroenterology.

[16]  M. Manns,et al.  ME3738 protects from concanavalin A‐induced liver failure via an IL‐6‐dependent mechanism , 2003, European journal of immunology.

[17]  Werner Müller,et al.  Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases , 2003, Hepatology.

[18]  Hiroaki Ito IL-6 and Crohn's disease. , 2003, Current drug targets. Inflammation and allergy.

[19]  G. S. Chhatwal,et al.  Immune mechanisms underlying host susceptibility to infection with group A streptococci. , 2003, The Journal of infectious diseases.

[20]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[21]  John D Lambris,et al.  Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression1 , 2003, The Journal of Immunology.

[22]  J. Siddiqui,et al.  Six at Six: Interleukin-6 Measured 6 H After the Initiation of Sepsis Predicts Mortality Over 3 Days , 2002, Shock.

[23]  A. Lengeling,et al.  Genetic control of susceptibility to group A streptococcal infection in mice. , 2001, The Journal of infectious diseases.

[24]  M. Colonna,et al.  TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.

[25]  Lisa R Leon,et al.  Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  D. Ilstrup,et al.  Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  R. Bone,et al.  Gram-positive organisms and sepsis. , 1994, Archives of internal medicine.

[28]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[29]  P. Brandtzaeg,et al.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.

[30]  H. Volk,et al.  Immunomodulatory therapies in sepsis , 2000, Intensive Care Medicine.

[31]  A. Norrby-Teglund,et al.  Correlation between serum TNF alpha and IL6 levels and severity of group A streptococcal infections. , 1995, Scandinavian journal of infectious diseases.